Overview of How Glp 1 Can Help In Treating Addiction Disorders

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug addiction , according to a new paper published in the Journal of the Endocrine Society. The therapies, known as Glucagon-Like Peptide-1 Receptor Agonists ( GLP -1RAs), present an encouraging approach to treating alcohol and other substance use disorders . "Early research in both ...

The Food and Drug Administration has approved GLP-1 medications for treating type 2 diabetes and obesity. Some doctors are prescribing these drugs off-label for a variety of addictive disorders . Research is under way on the effectiveness of treating addiction with these medications, and some initial studies have shown promising results.
The potential role of GLP

These findings imply that different GLP-1 receptor agonists might have differential efficacy across various substance use disorders , being more effective in treating alcohol and nicotine addiction but less so for opioid addiction .
The GLP-1 class of diabetes and obesity drugs show promise in treating and preventing all substance use disorders in a new study.

Can GLP
Clinical trials suggest Ozempic and Other GLP-1s may treat alcohol, opioid and nicotine addiction by rewiring the brain's reward system. Learn about the science, risks and off-label use.
Glucagon‐like peptide 1 ( GLP‐1 ) is released in the small intestine, promotes blood glucose homeostasis, slows gastric emptying and reduces appetite. GLP‐1 receptor agonists approved for treating Type 2 diabetes mellitus and obesity have received attention as a potential anti‐addiction treatment.

Five things to know about GLP
The Food and Drug Administration has approved GLP-1 medications for treating type 2 diabetes and obesity. Some doctors are prescribing these drugs off-label for a variety of addictive disorders .
Researchers have discovered that drugs like Ozempic for diabetes and obesity also improve alcohol use disorders and other addictions . This is a stunning gut-brain breakthrough.

Mechanisms of GLP
By integrating findings from molecular signaling, neurocircuitry, and behavioral models, this review provides a translational perspective on GLP -1RAs as an emerging treatment strategy in addiction medicine. We propose that targeting gut-brain metabolic signaling could provide a novel framework for understanding and treating SUDs.






This systematic review of clinical trials focusing on glucagon-like peptide-1 receptor agonists ( GLP -1RAs) for the treatment of substance use disorders (SUDs) has several important findings.